+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
MALE
ID06574880

Phase III Trial of Lu-PSMA-617 with Stereotactic Body Radiotherapy for Advanced Local Prostate Cancer in Men Age 18 and Older

Led by Angela Y. Jia, MD PhD · Updated on 2026-05-26

45

Participants Needed

1

Research Sites

25 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether using the drug Pluvicto instead of long-term androgen deprivation therapy ADT alongside radiation therapy can reduce the chance of prostate cancer returning and better preserve quality of life in men with advanced local prostate cancer. This trial also aims to assess the safety of combining Lu-PSMA-617 Pluvicto with stereotactic body radiation therapy SBRT to the prostate and pelvic lymph nodes, potentially avoiding the side effects linked to ADT and improving treatment adherence. Participants will receive one intravenous dose of Lu-PSMA-617, followed about 6 weeks later by five radiation treatments over two weeks targeting the prostate and pelvic lymph nodes. A second dose of Lu-PSMA-617 is given 6 weeks after completing radiation, and some participants may receive a third dose 6 weeks later depending on dose escalation levels. The study includes treatment cycles with specified timing to evaluate dose safety and effectiveness. During the study, participants will undergo assessments including prostate-specific antigen PSA tests, imaging scans like PSMA PETCT, quality of life questionnaires EPIC-26, XeQoLS, FACT-RNT, and monitoring for side effects and cancer progression over several years. The main outcomes include determining the maximum tolerated dose of Lu-PSMA-617 and measuring survival without ADT over 3 years. Follow-up evaluations will continue up to 5 years post-treatment to monitor survival, recurrence, toxicity, and quality of life changes.

CONDITIONS

Brief Title

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

Research Team

A

Angela Y Jia, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here